Lung Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, Lung Cancer - Pipeline Review, H1 2012, provides an overview of the Lung Cancer therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. Lung Cancer - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Cancer.
- A review of the Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lung Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Cancer pipeline depth and focus of Lung Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Introduction 14
Lung Cancer Overview 15
Therapeutics Development 16
Lung Cancer Therapeutics under Development by Companies 18
Lung Cancer Therapeutics under Investigation by Universities/Institutes 35
Late Stage Products 61
Mid Clinical Stage Products 62
Early Clinical Stage Products 63
Discovery and Pre-Clinical Stage Products 64
Lung Cancer Therapeutics – Products under Development by Companies 65
Lung Cancer Therapeutics – Products under Investigation by Universities/Institutes 99
Companies Involved in Lung Cancer Therapeutics Development 187
Lung Cancer – Therapeutics Assessment 397
Drug Profiles 405
Lung Cancer Therapeutics – Drug Profile Updates 526
Lung Cancer Therapeutics – Discontinued Products 554
Lung Cancer Therapeutics - Dormant Products 572
Lung Cancer – Product Development Milestones 644
Appendix 652

List of Tables

Number of Products Under Development for Lung Cancer, H1 2012 28
Products under Development for Lung Cancer – Comparative Analysis, H1 2012 29
Number of Products under Development by Companies, H1 2012 31
Number of Products under Development by Companies, H1 2012 (Contd..1) 32
Number of Products under Development by Companies, H1 2012 (Contd..2) 33
Number of Products under Development by Companies, H1 2012 (Contd..3) 34
Number of Products under Development by Companies, H1 2012 (Contd..4) 35
Number of Products under Development by Companies, H1 2012 (Contd..5) 36
Number of Products under Development by Companies, H1 2012 (Contd..6) 37
Number of Products under Development by Companies, H1 2012 (Contd..7) 38
Number of Products under Development by Companies, H1 2012 (Contd..8) 39
Number of Products under Development by Companies, H1 2012 (Contd..9) 40
Number of Products under Development by Companies, H1 2012 (Contd..10) 41
Number of Products under Development by Companies, H1 2012 (Contd..11) 42
Number of Products under Development by Companies, H1 2012 (Contd..12) 43
Number of Products under Development by Companies, H1 2012 (Contd..13) 44
Number of Products under Development by Companies, H1 2012 (Contd..14) 45
Number of Products under Development by Companies, H1 2012 (Contd..15) 46
Number of Products under Investigation by Universities/Institutes, H1 2012 48
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 49
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 50
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 51
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 52
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 53
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 54
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 55
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 56
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 57
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 58
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 59
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 60
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 61
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 62
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 63
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 64
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 65
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 66
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 67
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 68
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 69
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 70
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 71
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 72
Comparative Analysis by Late Stage Development, H1 2012 73
Comparative Analysis by Mid Clinical Stage Development, H1 2012 74
Comparative Analysis by Early Clinical Stage Development, H1 2012 75
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 76
Products under Development by Companies, H1 2012 77
Products under Development by Companies, H1 2012 (Contd..1) 78
Products under Development by Companies, H1 2012 (Contd..2) 79
Products under Development by Companies, H1 2012 (Contd..3) 80
Products under Development by Companies, H1 2012 (Contd..4) 81
Products under Development by Companies, H1 2012 (Contd..5) 82
Products under Development by Companies, H1 2012 (Contd..6) 83
Products under Development by Companies, H1 2012 (Contd..7) 84
Products under Development by Companies, H1 2012 (Contd..8) 85
Products under Development by Companies, H1 2012 (Contd..9) 86
Products under Development by Companies, H1 2012 (Contd..10) 87
Products under Development by Companies, H1 2012 (Contd..11) 88
Products under Development by Companies, H1 2012 (Contd..12) 89
Products under Development by Companies, H1 2012 (Contd..13) 90
Products under Development by Companies, H1 2012 (Contd..14) 91
Products under Development by Companies, H1 2012 (Contd..15) 92
Products under Development by Companies, H1 2012 (Contd..16) 93
Products under Development by Companies, H1 2012 (Contd..17) 94
Products under Development by Companies, H1 2012 (Contd..18) 95
Products under Development by Companies, H1 2012 (Contd..19) 96
Products under Development by Companies, H1 2012 (Contd..20) 97
Products under Development by Companies, H1 2012 (Contd..21) 98
Products under Development by Companies, H1 2012 (Contd..22) 99
Products under Development by Companies, H1 2012 (Contd..23) 100
Products under Development by Companies, H1 2012 (Contd..24) 101
Products under Development by Companies, H1 2012 (Contd..25) 102
Products under Development by Companies, H1 2012 (Contd..26) 103
Products under Development by Companies, H1 2012 (Contd..27) 104
Products under Development by Companies, H1 2012 (Contd..28) 105
Products under Development by Companies, H1 2012 (Contd..29) 106
Products under Development by Companies, H1 2012 (Contd..30) 107
Products under Development by Companies, H1 2012 (Contd..31) 108
Products under Development by Companies, H1 2012 (Contd..32) 109
Products under Development by Companies, H1 2012 (Contd..33) 110
Products under Investigation by Universities/Institutes, H1 2012 111
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 112
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 113
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 114
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 115
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 116
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 117
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 118
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 119
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 120
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 121
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 122
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 123
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 124
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 125
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 126
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 127
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 128
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 129
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 130
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 131
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 132
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 133
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 134
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 135
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 136
Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 137
Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 138
Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 139
Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 140
Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 141
Products under Investigation by Universities/Institutes, H1 2012 (Contd..31) 142
Products under Investigation by Universities/Institutes, H1 2012 (Contd..32) 143
Products under Investigation by Universities/Institutes, H1 2012 (Contd..33) 144
Products under Investigation by Universities/Institutes, H1 2012 (Contd..34) 145
Products under Investigation by Universities/Institutes, H1 2012 (Contd..35) 146
Products under Investigation by Universities/Institutes, H1 2012 (Contd..36) 147
Products under Investigation by Universities/Institutes, H1 2012 (Contd..37) 148
Products under Investigation by Universities/Institutes, H1 2012 (Contd..38) 149
Products under Investigation by Universities/Institutes, H1 2012 (Contd..39) 150
Products under Investigation by Universities/Institutes, H1 2012 (Contd..40) 151
Products under Investigation by Universities/Institutes, H1 2012 (Contd..41) 152
Products under Investigation by Universities/Institutes, H1 2012 (Contd..42) 153
Products under Investigation by Universities/Institutes, H1 2012 (Contd..43) 154
Products under Investigation by Universities/Institutes, H1 2012 (Contd..44) 155
Products under Investigation by Universities/Institutes, H1 2012 (Contd..45) 156
Products under Investigation by Universities/Institutes, H1 2012 (Contd..46) 157
Products under Investigation by Universities/Institutes, H1 2012 (Contd..47) 158
Products under Investigation by Universities/Institutes, H1 2012 (Contd..48) 159
Products under Investigation by Universities/Institutes, H1 2012 (Contd..49) 160
Products under Investigation by Universities/Institutes, H1 2012 (Contd..50) 161
Products under Investigation by Universities/Institutes, H1 2012 (Contd..51) 162
Products under Investigation by Universities/Institutes, H1 2012 (Contd..52) 163
Products under Investigation by Universities/Institutes, H1 2012 (Contd..53) 164
Products under Investigation by Universities/Institutes, H1 2012 (Contd..54) 165
Products under Investigation by Universities/Institutes, H1 2012 (Contd..55) 166
Products under Investigation by Universities/Institutes, H1 2012 (Contd..56) 167
Products under Investigation by Universities/Institutes, H1 2012 (Contd..57) 168
Products under Investigation by Universities/Institutes, H1 2012 (Contd..58) 169
Products under Investigation by Universities/Institutes, H1 2012 (Contd..59) 170
Products under Investigation by Universities/Institutes, H1 2012 (Contd..60) 171
Products under Investigation by Universities/Institutes, H1 2012 (Contd..61) 172
Products under Investigation by Universities/Institutes, H1 2012 (Contd..62) 173
Products under Investigation by Universities/Institutes, H1 2012 (Contd..63) 174
Products under Investigation by Universities/Institutes, H1 2012 (Contd..64) 175
Products under Investigation by Universities/Institutes, H1 2012 (Contd..65) 176
Products under Investigation by Universities/Institutes, H1 2012 (Contd..66) 177
Products under Investigation by Universities/Institutes, H1 2012 (Contd..67) 178
Products under Investigation by Universities/Institutes, H1 2012 (Contd..68) 179
Products under Investigation by Universities/Institutes, H1 2012 (Contd..69) 180
Products under Investigation by Universities/Institutes, H1 2012 (Contd..70) 181
Products under Investigation by Universities/Institutes, H1 2012 (Contd..71) 182
Products under Investigation by Universities/Institutes, H1 2012 (Contd..72) 183
Products under Investigation by Universities/Institutes, H1 2012 (Contd..73) 184
Products under Investigation by Universities/Institutes, H1 2012 (Contd..74) 185
Products under Investigation by Universities/Institutes, H1 2012 (Contd..75) 186
Products under Investigation by Universities/Institutes, H1 2012 (Contd..76) 187
Products under Investigation by Universities/Institutes, H1 2012 (Contd..77) 188
Products under Investigation by Universities/Institutes, H1 2012 (Contd..78) 189
Products under Investigation by Universities/Institutes, H1 2012 (Contd..79) 190
Products under Investigation by Universities/Institutes, H1 2012 (Contd..80) 191
Products under Investigation by Universities/Institutes, H1 2012 (Contd..81) 192
Products under Investigation by Universities/Institutes, H1 2012 (Contd..82) 193
Products under Investigation by Universities/Institutes, H1 2012 (Contd..83) 194
Products under Investigation by Universities/Institutes, H1 2012 (Contd..84) 195
Products under Investigation by Universities/Institutes, H1 2012 (Contd..85) 196
Products under Investigation by Universities/Institutes, H1 2012 (Contd..86) 197
Products under Investigation by Universities/Institutes, H1 2012 (Contd..87) 198
Bristol-Myers Squibb Company, H1 2012 199
Johnson & Johnson, H1 2012 200
Boehringer Ingelheim GmbH, H1 2012 201
F. Hoffmann-La Roche Ltd., H1 2012 202
Kyowa Hakko Kirin Co., Ltd., H1 2012 203
Abbott Laboratories, H1 2012 204
Biogen Idec Inc., H1 2012 205
Helix BioPharma Corp., H1 2012 206
Amgen Inc., H1 2012 207
Sanofi-Aventis, H1 2012 208
AstraZeneca PLC, H1 2012 209
Eli Lilly and Company, H1 2012 210
Viralytics Ltd., H1 2012 211
GlaxoSmithKline plc, H1 2012 212
Seattle Genetics, Inc., H1 2012 213
Genentech, Inc., H1 2012 214
Antigenics, Inc., H1 2012 215
Isis Pharmaceuticals, Inc., H1 2012 216
Daiichi Sankyo Company, Ltd, H1 2012 217
Merck & Co., Inc., H1 2012 218
Dainippon Sumitomo Pharma Co., Ltd., H1 2012 219
A&G Pharmaceutical, Inc., H1 2012 220
Infinity Pharmaceuticals, Inc., H1 2012 221
Albany Molecular Research, Inc., H1 2012 222
YM BioSciences Inc., H1 2012 223
Light Sciences Oncology, Inc., H1 2012 224

List of Figures

Number of Products under Development for Lung Cancer, H1 2012 28
Products under Development for Lung Cancer – Comparative Analysis, H1 2012 29
Products under Development by Companies, H1 2012 30
Products under Investigation by Universities/Institutes, H1 2012 47
Late Stage Products, H1 2012 73
Mid Clinical Stage Products, H1 2012 74
Early Clinical Stage Products, H1 2012 75
Discovery and Pre-Clinical Stage Products, H1 2012 76
Assessment by Monotherapy Products, H1 2012 409
Assessment by Combination Products, H1 2012 410
Assessment by Route of Administration, H1 2012 411
Assessment by Stage and Route of Administration, H1 2012 412
Assessment by Molecule Type, H1 2012 414
Assessment by Stage and Molecule Type, H1 2012 415